Mineralys Therapeutics, Inc. MLYS Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s return on assets?
- Mineralys Therapeutics, Inc. (MLYS) reported return on assets of -30.1% in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s return on assets changed year-over-year?
- Mineralys Therapeutics, Inc.'s return on assets increased by 43.9% year-over-year, from -53.7% to -30.1%.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s return on assets?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s return on assets has grown at a -4.7% compound annual growth rate (CAGR), from -39.3% to -35.6%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.